Congratulations to Dr. Ed Reznik on his 2019 Young Investigator Award from the Kidney Cancer Association on Metabolic determinants of the tumor microenvironment and sensitivity to immunotherapy in ccRCC.
The introduction of immunotherapy has transformed the management of advanced kidney cancer. Although many kidney cancer patients benefit from immunotherapy, there is a formidable gap in our understanding of why a large fraction of patients fail to respond, and why those who do respond eventually become resistant. This research will evaluate the widely proposed, but narrowly explored, role that kidney tumor metabolism plays in the response to immunotherapy.
An excerpt about Dr. Reznik’s research